meningococcal meningitis
TRANSCRIPT
![Page 1: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/1.jpg)
Meningococcal Meningitis
Presented by Dr Nazrul Islam AGMC Agartala
![Page 2: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/2.jpg)
Meningococcal Infections
• Neisseria meningitidis (meningococcus)
• Gram negative, diplococcus bean shaped
• Found only in man
![Page 3: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/3.jpg)
13 serogroups by surface capsular polysaccharide
A, B, C, Y and W frequent isolates
from meningococcal disease Other groups isolated from carriers
Meningococcal Infections
![Page 4: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/4.jpg)
• Common in temperate and tropical climates
• Nov. to March
• Carriage rates: healthy children upto 10%
• Transmitted via contact with respiratory secretions
Meningococcal Infections
Neisseria meningitidis
![Page 5: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/5.jpg)
DISESES CAUSED BY MENINGOCOCCUS
• Meningitis – 50%• Bacteremia – 35%-40% • Pneumonia – 9%• Other focal infection like Myocardium Pericardium Joints Eye Peritonium Sinuses Middle ear Urethritis Cervicitis Vulvovaginitis Orchitis
![Page 6: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/6.jpg)
Meningococcal InfectionsDisease may occur following
exposure to carriers or infected patients within the family, day care and military camps
Occurs most frequent:(< 5 yrs old )Peak attack rate : 6-12 months old
2nd peak attack rate: 15-19 yrs of age
![Page 7: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/7.jpg)
1Pollard. In: Harrison's Principles of Internal Medicine. 18th ed. 2012;chapter 143; 2Bilukha. Pediatr Infect Dis J. 2007;26(5); 3MacNeil. In: Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. 2012; 4Liphaus. Enferm Infecc Microbiol Clin. 2013;31(2)
Impaired immune system1,2/lack of antibodies1
Exposure through close contact with infected person or the live bacteria
Travelers to endemic areas3
Immunocompromised2
Infants, children1,2 Caregivers3
Personnel working with N. meningitidis2,3
Crowding1,3,4
(students, military, Hajj, oil refineries)
At-Risk Populations
![Page 8: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/8.jpg)
Incidence Rates (cases/100,000 inhabitants) for Latin America
Countries of Region 1, 1980–2011
1Safadi. First Regional Meningococcal Symposium 2012; March 19-20, 2012, Buenos Aires, Argentina.
Argentina
ChileBrazil
Uruguay
80–81
2010–201182–83
84–8586–87
88–8990–91
92–9394–95
96–9798–99
2000–2001
2002–2003
2004–2005
2006–2007
2008–20090
1
2
3
4
5
6
7
8
![Page 9: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/9.jpg)
A. Greenbaum et al. Global Estimates of Meningococcal Meningitis Case Fatality Ratios by Region for Children and Adults. Idweek 1164, San Diego, Oct 2015
Studies conducted between 1980 to 2014 & n≥20 cases
< 5 yrs age
20-64 yrs age
Asia: CFR of Meningococcal Meningitis
![Page 10: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/10.jpg)
• Disease is endemic in India and several major epidemics
reported across India especially from Delhi and surrounding
districts
• Disease occurs in dry season
• Surviellance:– Notifiable disease under Integrated Disease Surveillance Programme (IDSP)– Part of IAP ‘ID Surv’ program under acute bacterial meningitis
• Serogroup A majorly responsible for both endemic disease
and epidemics in India
• Some prevalence of disease due to Serogroup C, B & W also
reported. 1. D. Sinclair et al. Tropical Medicine and International Health 2010;15(12):1421-35 2. Manchanda V et al. Indian J Med Microbiol 2006;24(1): 7-19 3. Aggarwal M. Indian Pediatrics 2013;50: 601-3
Epidemiology in India
![Page 11: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/11.jpg)
Year Location Suspected cases
Deaths
1966-67 Delhi 616 1291985-88 Delhi 6133 7991985-88 Maharashtra 15731985-87 Surat 197 342005-09 Delhi 1725 1082008 Meghalaya ~2000 ~ 2002009 Tripura ~ 200 ~50
D. Sinclair et al. Tropical Medicine and International Health 2010;15(12):1421-35; V Manchanda et al. Indian J Med Microbiol 2006;24(1): 7-19; CD Alert. NCDC.DGHS.November 2009.13(3)
Prevalence & Distribution of Neisseria meningitidis isolates during epidemic periods
![Page 12: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/12.jpg)
National Health Profile , India 2006-2015, Central Bureau of Health Intelligence. Available at http://cbhidghs.nic.in
Meningococcal Meningitis Cases & Deaths in India
![Page 13: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/13.jpg)
Out break of Tripura 22nd Jan 2009 from Dhalai dist 1st report ( Chawmanu block) Confirm on 7th Jan 2009 Last case Aug. 2009(peak May 2009) Confirmed cases was 285 Deaths 62. CF 22%
District Population (L)
No. of cases Attack rate/ 1 L
No. of death Case fatality rate
South 7.7 14 1.8 6 43
West 16.4 13 0.8 3 23
North 5.8 35 6 7 20
Dhalai 3.6 223 6.1 46 21
Tripura 33.7 285 8.4 62 22
Indian journal of Medical microbiology, Jan –March 2011
![Page 14: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/14.jpg)
Pathogenesis/Pathology
Meningococci colonize the nasopharynx penetrate mucosal surface transported by leukocytes to blood stream hematogenous dissemination localizes: heart, CNS, skin, mucous and serous membranes adrenals
![Page 15: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/15.jpg)
ENDOTOXEMIA
Release of IL and TNF
hypotension multi-organ system failure
Diffusevasculitis
*Complement activation
DIC
Haemorrhage and necrosis in any organ bleeding into adrenals in patients with septicemia and shock
Waterhouse- Friderichsen syndrome
![Page 16: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/16.jpg)
IMD is difficult to diagnose and rapidly lethal
• Flu-like nature of early symptoms makes a definitive diagnosis challenging1
• Rapid progression, with death in as little as 24 hours1,2
1Thompson et al. Lancet. 2006;367(9508); 2Branco et al. J Pediatr (Rio J). 2007;83(2 suppl)
12–15 Hours1,2
Characteristic15–~24 Hours1,2
Late4–8 Hours1,2
NonspecificFever, irritability, nausea or vomiting,
drowsiness, poor appetite, sore throat, coryza, general aches
Hemorrhagic rash, neck stiffness,photophobia
Confusion or delirium, seizure, unconsciousness;
possible deathHospital admission at median of ~19
hours1
![Page 17: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/17.jpg)
• Meningococcal meningitis clinically indistinguishable from meningitis
due to other bacteria. Non-blanching petechial rash is present in only
a few cases. 1.
• In a study of 110 cases of IMD from a tertiary care hospital in
Meghalaya from Jan 08 –June 09 during an outbreak 2
• In the same study, meningococcal meningitis was seen in 61.8% of
cases, meningococcemia in 20 %. 18.2% had both.
1. Nelson text book of Pediatrics. 19th Ed. 2. Hazarika RD et al, Indian J Pediatr 2012 doi:10.1007/s12098-012-0855-0
100
56.4 53.6
23.69.1 6.4
0
50
100
Fever Headache Vomiting Rashes Seizures Deaths
Clinical profile of 110 cases of IMD
%
Rash is not so common in the absence of fulminant meningococcaemia
![Page 18: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/18.jpg)
![Page 19: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/19.jpg)
![Page 20: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/20.jpg)
![Page 21: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/21.jpg)
Features Indicating Bad Prognosis
• (+) petechial < 12 hrs prior to admission• (+) hypotension• absence of meningitis• WBC < 10,000/mm3• ESR < 10 mm/hr.
Interpretation: (+) 3 or > features: 90% mortality > 2 features; 9% mortality
![Page 22: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/22.jpg)
Other Poor Prognostic Sign
• Rapid progression of petechia to ecchymoses
or purpura • Wakefulness• Poor skin perfusion• respiratory distress• thrombocytopenia• advanced age
![Page 23: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/23.jpg)
DiagnosisMaintain a high index of suspicion
1. Gm stain of petechial scrapings, blood CSF 2. Buffy coat of blood
3. Culture of blood, CSF, petechial scraping, synovial fluid, sputum and other body fluids
4. Antigen detection tests (CSF, urine, serum) latex agglutination, --lack adequate sensitivity and specificity
![Page 24: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/24.jpg)
TreatmentEmpirical 3rd gen Cephalosporin Vancomycin in region with high rate of beta lactum resi. S. pneumoniae
Penicillin G 300,000 u/k/day IV 6 div doses Alternatives : Cefotaxime 200 mg/k/d Ceftriazone 100 mg/k/day
If allergic to B-lactams : Chloramphenicol 75-100 mg/kg dCiprofloxacin 30-40mg/k/dMeropenem 60-120mg/kg/d
![Page 25: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/25.jpg)
ISOLATION: RESPIRATORY isolation until 24hrs after effective antibioticsChemoprophylaxisAll Close contact & lasting >8hrs 7 days before onset of DISEASE• DOC: Rifampicin 10 mg/kg >1 mon, 5 mg/kg in <1
mon• (max 600 mg) q 12hrlyx 2 days
• other drugs: Ceftriaxone Ciprofloxacin Azithromycinmeningococcal vaccine can be used with chemoprophylaxis since 2° cases may occur several weeks later
![Page 26: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/26.jpg)
ComplicationsAdrenal haemorrhage ,waterhouse friderichsen
syndrome Endophthalmatis ArthritisEndocarditis , myocarditis, pericarditisPneumonia, lung abscessPeritonitisRenal infarcts, AKIReactivation of latent herpes simplex virus infection Focal skin infarction(mainly lower limb)Skeletal deformity Deafness Stroke, subdural effusion Ataxia, seizure, blindness, obstuctive hydrocephalus Behavioral and psychosocial complication
![Page 27: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/27.jpg)
Case Series from 10 Children’s Hospitals
Sequelae distribution
amongsurvivors
n = 146
Mortalityn = 159
Percent ofpatients
1.4
2.1
2.8
6.2
9.6
9.6
4.8
21.2
8.0
0 5 10 15 20 25
Amputation
Hemiplegia
Ataxia
Seizures
Skin Necrosis
Hearing Loss
≤11 Years (n=126)
≥11 Years (n=33)
Overall
Kaplan SL, et al. Pediatrics. 2006;118:e979
Percent of patients
27|
Meningococcal Disease: Death and Disability
![Page 28: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/28.jpg)
![Page 29: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/29.jpg)
Prevention
![Page 30: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/30.jpg)
Types of Meningococcal Vaccines
Capsular
Capsular
Non
• Plain Polysaccharide mono, bi, tri or tetravalent0.5 ml SC/IM
• Conjugate vaccines.5ml deep IM• Monovalent A (MenAfrivac)* & C*• Quadrivalent ACWY
A, C, W
Y B
• OMV, OMP Recombinant vaccines
• Not available in India yetCarrier Protein Vaccine
DT Menactra
TT Nimenrix*
Serogroup B antigen has a great similarity with the polysaccharide epitopes of human nerve tissues, it has an immune tolerance to serogroup B capsule1.
1. Halil Özdemir et al. J Pediatr Inf 2014; 8: 178-86
![Page 31: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/31.jpg)
B C Y W
B C Y W
B C
B C Y W A
A WA B W
B Y W
B C B C
A
Global Distribution of epidemic N. meningitidis serogroups1
1. Kate O'Brien. Meningococcal A Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) Geneva, 22 October 2014
2. D. Sinclair et al. Tropical Medicine and International Health 2010;15(12):1421-353. David S Stephens et al. Epidemic meningitis, meningococcaemia, and Neisseria Meningitidis. Lancet 2007; 369: 2196–210
A C
2
3
![Page 32: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/32.jpg)
• Countries with intermediate or high (2-10 or >10 cases/ 100000
population/year) endemic rates of IMD or with frequent
epidemics introduce appropriate large scale vaccination
programmes
• Countries where disease occurs less frequently (<2 cases/ 100 000 population/year),
vaccination is recommended for defined risk groups:
o Children and young adults residing in closed communities, e.g. boarding
schools or military camps.
o Laboratory workers at risk of exposure to meningococci
o Travellers to high endemic areas
o All individuals suffering from immunodeficiency including asplenia, terminal
complement deficiencies, or advanced HIV infection
WHO recommendations 2011 : meningococcal vaccination
WHO position paper November 2011-11-28
![Page 33: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/33.jpg)
IAP recommendation of MCV Only for certain high risk condition and situation. In children 2yrs or more (3mon or more in risk of
outbreaks/close household contact). Conjugated vaccines preferred over polysaccharide
vaccine due to herd protection and high immunogenicity.
During outbreaks Children with terminal complement defiencies -2
doses primary series 8-12 wks apart in>2yrs and booster every 5 yrs
Children with functional/anatomic asplenia/hyposplenia.
If Splenectomy required Vacctionation should ideally be started 2 wks prior to splenectomy.
![Page 34: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/34.jpg)
Person with HIV Laboratory personal and health workers Student going for study abroad Hajj pilgrims Travelers to African meningitis beltOut break3 or more cases of meningococcal disease have occured in either an organization or a community base outbreak during less then 3 months
![Page 35: Meningococcal meningitis](https://reader034.vdocuments.mx/reader034/viewer/2022052418/5885a2671a28abd2498b7585/html5/thumbnails/35.jpg)
THANKING YOU